All In Biotech

Drug Trial Radar · NCT01178125

A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-102) for the Prevention of Pregnancy in Women

Last checked: Nov 19, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,858

Actual

Start

Aug 2010

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Sponsor type
Industry
First posted
Aug 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, single treatment study. All subjects will receive 12 months of oral contraceptive therapy with DR-102. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a daily diary.

Conditions

  • Contraception
  • Female Contraception

Interventions

  • DR-102Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day RuleTime frame: thirteen 28-day cycles
  2. Typical-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day RuleTime frame: thirteen 28-day cycles
  3. Compliant-Use Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day RuleTime frame: thirteen 28-day cycles

Locations

62 sites in 2 countries. Site status is shown where the registry gives one.

  • Teva Investigational Site 10007

    Montgomery, Alabama

  • Teva Investigational Site 10013

    Phoenix, Arizona

  • Teva Investigational Site 10017

    Phoenix, Arizona

  • Teva Investigational Site 10032

    Little Rock, Arkansas

  • Teva Investigational Site 10026

    San Diego, California

  • Teva Investigational Site 10056

    San Diego, California

  • Teva Investigational Site 10002

    Colorado Springs, Colorado

  • Teva Investigational Site 10033

    Colorado Springs, Colorado

  • Teva Investigational Site 10057

    Washington D.C., District of Columbia

  • Teva Investigational Site 10052

    Clearwater, Florida

  • Teva Investigational Site 10021

    Jacksonville, Florida

  • Teva Investigational Site 10036

    Leesburg, Florida

  • Teva Investigational Site 10012

    Miami, Florida

  • Teva Investigational Site 10015

    Miami, Florida

  • Teva Investigational Site 10055

    Palm Beach Gardens, Florida

  • Teva Investigational Site 10001

    West Palm Beach, Florida

  • Teva Investigational Site 10031

    Decatur, Georgia

  • Teva Investigational Site 10041

    Roswell, Georgia

  • Teva Investigational Site 10050

    Savannah, Georgia

  • Teva Investigational Site 10008

    Louisville, Kentucky

  • Teva Investigational Site 10023

    Mount Sterling, Kentucky

  • Teva Investigational Site 10048

    Lawrenceville, New Jersey

  • Teva Investigational Site 10030

    Moorestown, New Jersey

  • Teva Investigational Site 10014

    Albuquerque, New Mexico

  • Teva Investigational Site 10006

    Rochester, New York

  • Teva Investigational Site 10044

    Cary, North Carolina

  • Teva Investigational Site 10040

    Charlotte, North Carolina

  • Teva Investigational Site 10034

    New Bern, North Carolina

  • Teva Investigational Site 10018

    Winston-Salem, North Carolina

  • Teva Investigational Site 10046

    Winston-Salem, North Carolina

  • Teva Investigational Site 10022

    Columbus, Ohio

  • Teva Investigational Site 10039

    Columbus, Ohio

  • Teva Investigational Site 10028

    Oklahoma City, Oklahoma

  • Teva Investigational Site 10043

    Philadelphia, Pennsylvania

  • Teva Investigational Site 10003

    Pittsburgh, Pennsylvania

  • Teva Investigational Site 10049

    Bluffton, South Carolina

  • Teva Investigational Site 10037

    Columbia, South Carolina

  • Teva Investigational Site 10035

    Greenville, South Carolina

  • Teva Investigational Site 10047

    Mt. Pleasant, South Carolina

  • Teva Investigational Site 10016

    Jackson, Tennessee

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.